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Tumornecrosis factor/cachectin (TNF), initially perceived as asecretory product
of activated macrophages, is a potent proinflammatory polypeptide (1, 2) . A wide
range of,biological outcomes have been ascribed to this hormone that is now recog-
nized to be secreted by additional cells of the immune system, includingT cells (3) .
TNF, on the one hand, is thought to contribute to the host armamentarium in the
arena of defence against infectious agents and in the control oftumor growth . On
the other hand,TNF has also been implicated as a major mediator of septic shock
andofcachexia associated with chronic disease states .Apossible reason forthe differen-
tialoutcomes might reside in thequantitative rather than qualitative aspects ofTNF
physiology ; "appropriate" amountsofTNF being protective to the host and an excess
being deleterious .Aqualitative explanationmightbe that the cell-bound rather than
secreted version of TNF is advantageous to the host . In this line of reasoning, we
have examined whether activated normal humanT cells displayTNF on their cell
surface. Our line of enquirywas prompted also by an earlier report ofinduced human
monocytes expressing TNF on their cell surface (4) .
Our first demonstration that normal human T cells, signaled with a synergistic
combination of 12-o-tetradecanoyl phorbol-13-acetate (TPA) and ionomycin, display
TNF on their cell surface forms the basis ofthis report . Furthermore, we show that
the cell surface TNF is -26 kD, and that cyclosporine (CsA) and methylpredniso-
lone (MP), blocktheexpression ofTNF inTcells atapretranslational site (byNorthern
analysis forTNRspecific transcripts) . Our observations confirm and extend the ob-
servation that induced human monocytes express a membrane version ofTNF (4),
and are in broad agreement with an elegant study (published while this manuscript
was in preparation) that murine cytotoxic cell lines express a membrane-bound
cytotoxin that is immunologically related to TNF (5) . More importantly, our data
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provide a mechanism by which the effects ofTNF can be realized locally in an antigen-
specific fashion.
Materials and Methods
Isolation andActivation of TCells.
￿
Highly purified T cells were isolated from normal human
PBMC with a sequential four-step procedure: depletion of monocytes by sephadex-G 10 gel
filtrationand by L-leucine methyl ester (5 mM; Sigma Chemical Co., St. Louis, MO) treat-
ment, depletion of residual DR' cells and NK cells by pretreatment with anti-DR and anti-
NKH-1 mAbs, by "panning" the antibody-labeled cells in petri dishes coated with goat
anti-mouse IgG, and utilization of SRBC-rosetting method as the finalpreparative step. FACS
analysis ofcells isolated revealed >99% ofcells to be positive for the CD2 antigen and <1%
of cells to be positive for the DR, NKH-1, or monocyte (M3) antigens.
T cellswere activated with TPA (1 ng/ml) and the calcium ionophore, ionomycin (0.5 /AM).
The cells (106 cells/ml) were suspended in RPMI 1640 medium supplemented with 5% heat-
inactivated autologous or pooled human AB serum, and antibiotics, and were incubated at
37°C in 5% C02, 951 7o air humidified atmosphere.
FACSAnalysisfor Cell Surface TNF .
￿
Tcellswere incubated with murine anti-human TNF
mAb (SDW-18.1 .1, ATCC cell line, HB9228) for 45 min at 4°C, washed twice in PBS, and
stained with FITC-conjugated goat anti-mouse IgGI antibody. A purified mouse monoclonal
IgG1 was used as a relevant isotype control. The percentage of cells positive for cell surface
TNF and the logarithmic mean channel fluorescence intensity of TNT-positive cells were
determined by analysis of immunofluorescence histograms, with Epics C multi-data acquisi-
tion and display system, software version 3.1, as described (6).
Cell Surface Labeling ofIntact Cells.
￿
Stimulatedor unstimulated T cells were incubated on
ice for 20 min in glass vials coated with lodogen, prepared as described by supplier (Pierce
Chemical Co., Rockford, IL), to which 1 mCi '2'I had been added, and the reaction was
terminated by removing the cells from the vials. Cells were washed with 150 mM NaI and
then three times in cold, phosphate-buffered NaCl (150 mM) . The cells were lysed by the
addition of 1 ml of lysis buffer (50 mM Tris, pH 7.4, 1% NP-40, 0.25% Na deoxycholate
[DOC], 150 mM NaCl, 5 mM EDTA, and 1 mM PMSF). Nuclei and other cellular debris
were removed by centrifugation. 10 jl murine antiTNF mAb preabsorbed to protein
A-sepharose was added to the cleared lysates, and immunoprecipitation was performed for
2 h at 4°C. The immunoprecipitates were washed three times in cold RIPA buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 1% DOC, 0.1% SDS), solubilized in SDS-PAGE
loading buffer, and subjected to electrophoresis in a 12% polyacrylamide gel. The gel was
fixed, dried, and exposed to film for 4 d with an intensifying screen.
Northern Blot Analysis.
￿
Total RNA was extracted from T cells by the guanidine isothio-
cyanate/cesium chloride method and quantitated by absorbance at 260 nm. RNA samples
(10 hg) were subjected to electrophoresis through a 1.2% agarose/2 .2 M formaldehyde gel,
transferred onto a nylon membrane by capillary action, and baked at 80°C for 2 h. After
prehybridization, the blot was allowed to hybridize with a 12P nick-translated pUC-9 plasmid
containing the mouse cachectin complementary DNA insert (7). Hybridization was carried
out at 42 °C for 12 h in the presence of50% formamide, 5 x SSC, 0.1% SDS, and 2.5 x Den-
hardts. The membrane was washed in 0.1 x SSC, 0.1% SDS at 42°C, and exposed to Kodak
film at -70°C for 48 h using an intensifying screen.
Results and Discussion
Activated Normal Human T Cells Express TNF on their Cell Surface.
￿
T cells execute
a variety of immune effector functions via a direct cell to cell contact. This unique
functional attribute is critical to the T cell's antigen-specific immunosurveillance capa-
bilities. Given T cells' ability to secrete TNF, and TNF's role in tumorlysis, we con-
sidered the possibility that activated T cells might be equipped with TNF on their
cell surface.KINKHABWALA ET AL .
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We tested the hypothesis that stimulated normal human T cells express surface
TNF by FAGS analysis of highly purified T cells signaled with a synergistic combi-
nation ofTPA, an activator of protein kinase C (PKC), andahighly specific calcium
ionophore, ionomycin . Results from a representative experiment are shown in Fig.
1 to illustrate several consistent findings : (a) activatednormalhumanT cells express
TNF on their cell surface ; (b)TPA andionomycin are synergistic in promoting cell
surface expression of TNF; and (c) neither activation o£ PKC alone with TPA nor
mobilization of calcium alone with ionomycin is sufficient for the induction of cell
surface expression of TNF in T cells.
Several features of our experimental approach are worthy of emphasis : (a) use of
normal human T cells rather than T cell clones or lines for the detection ofa cell
surface version ofTNF; (b) use of highly purifiedT cells preparations, obviating
the possibility of monocyte contamination of the T cell samples. This is an impor-
tant consideration in light of an earlier demonstration of a cell surface version of
TNF in human monocytes (4); (c) use of a mAb rather than polyclonal antibody
directed at human TNF for the demonstration of cell surfaceTNF; and (d) use of
an isotypic control mAb during FAGS analysis to distinguish nonspecific (Fc
receptor-related) fluorescence signal from the specific fluorescence signal resulting
from the binding of antiTNF mAb to the cell surface TNF .
T Cell Surface TNF Is-26W .
￿
Kriegler et al. (4) haveshown that aTNFproducing
cell line has a membrane version ofTNF of-26kD (size predicted byTNFcDNA).
Herein, we have determined the relative molecular mass of cell surface TNF dis-
played by stimulated normal humanT cells .
FIGURE 1.
￿
ActivatedT cells expressTNF on their cell surface. Highly purified normal human
T cells were incubated for 1, 4, or 16 h with 1 ng/ml TPA alone (A), 0.5 AM ionomycin alone
(B), or TPA + ionomycin together (C. FRCS analyses is shown after labeling ofT cells with
IgGl antiTNF mAb and FITC-conjugated goat anti-mouse IgGl . The percentage ofT cells
positive for cell surfaceTNF (numbers in each panel) was determined by analysis of immunofluores-
cence histograms using EpicsC multidata acquisition and display systems, software version 3 .1 .
T cells incubated alone in the absence ofTPA or ionomycin, and for similar duration, and then
labeled with IgG1 antiTNF mAb and FITC-goat anti-mouse IgG1 were used to determine the
background fluorescence signal .944
￿
KINKHABWALA ET AL.
￿
BRIEF DEFINITIVE REPORT
T cells triggered with TPA and ionomycin or unstimulated T cells were surface
labeled with 1251, lysed, and the cell lysates were immune precipitated with mAbs
directed at TNF. Results from this experimental approach are illustrated in Fig. 2.
It is evident that T cells signaled with TPA and ionomycin, and not unstimulated
T cells, express the 26-kD polypeptide (Fig. 2, lane 2 vs. 1). Immune precipitation
with antiTNF mAb ofcell lysatesofstimulated T cellsresulted also in thedetection
oftwo additional proteins ofhigher molecular mass, one polypeptide in the range
of 50-60 kD, and the other in the range of 70-80 kD. In this context, it is worth
noting that Liu et al. (5) have recently detected a50-60-kD polypeptide in a murine
cytotoxic Tcelllineby surface iodination and immuneprecipitation withpolyclonal
antiTNF antibody. Also, the active form ofTNF is thought to be a trimeric mole-
cule formed by an unusual arrangement between individual subunits of TNF (8).
The secreted form ofTNF is -17 kD. The lack ofa polypeptide with the relative
molecular mass of 17 kD in our immune precipitates of stimulated T cells argues
strongly against the possibility that the cell surface TNF identified in our studies
is due to the secreted form of TNF that has been adsorbed to the T cell surface.
Moreover, TPA andotheractivators ofPKC preventthebindingofTNFtoits receptor
(9), and our experimental conditions (use ofTPA to generate one ofthe signals re-
quired for Tcell activation) negate the possibility that the secreted TNF bound to
the T cell surface via the TNF receptor is responsible for the display of TNF by
activated T cells.
CsA orMPInhibit T CellSurface Expression of TNF .
￿
Corticosteroids inhibit thesecre-
tion of several monocyte-derived inflammatory polypeptides, including TNF (7).
CsA, a potent immunosuppressant, prevents the production ofT cell-derived lym-
phokines but not the secretion ofIL-1 or TNF by monocytes (10). It was therefore
ofinterest to determine the effect ofsteroids and CsA on the expression ofcell sur-
face TNF by stimulated T cells.
Fig. 3 illustrates the inhibitory effects ofCsA and MP on cell surface expression
ofTNF by T cells activated with TPA and ionomycin. At all time intervals tested,
the immunosuppressants used clearly reduced the cell surface expression of TNF.
The ability of CsA to prevent cell surface expression of TNF was also evident by
radioiodination and immune precipitation ofstimulated T cells (data not shown).
Transcriptional Activation ofthe TNF Gene in Stimulated T Cells and Reduction of TNF
mRNA by CsA and MP . Transcriptional, as well as post-transcriptional, regulation
of TNF expression have been reported. Beutler et al. (7) have demonstrated that
dexamethasone prevents the increase in TNF mRNAcontent resulting from stimu-
lation ofmurine macrophages with endotoxin. Granelli-Piperno et al. (10), on the
otherhand, found that CsA failed to prevent TNF mRNA accumulation in human
monocytestriggered with TPA andConA. Given ourobservation thatCsA prevents
the cell surface expression ofTNF, it was of interest to locate the sites of action of
CsA with respect toTNFgene expression andcompareitwith that ofcorticosteroids.
Fig. 4 summarizes the induction ofTNF mRNA production in T cells activated
with TPA and ionomycin, and the inhibitory activity of CsA and MP Northern
blot analysis revealed: (a) lack ofTNF mRNA in unstimulated T cells (Fig. 4, lane
1); (b) accumulation ofTNF mRNA in T cells triggered with TPA and ionomycin
(lane 2); and (c) reduction ofTPA and ionomycin induced TNF mRNA accumula-KINKHABWALA ET AL .
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(Fig . 2, left) Presence of26-kD TNF on the surface of activated normal humanT cells .
Surface labeling andimmune precipitation with antiTNFmAbofcell lysates ofT cells incubated alone
for 16 h (lane 1) orT cells stimulated withTPA (1 ng/ml) and ionomycin (0.5wM).The 26-kD polypep-
tide, a size predicted by TNF cDNA and found only in stimulatedT cells, is indicated by the arrow.
(Fig . 3, middle)CsAandMP inhibit cell surface expression ofTNF . The percentage ofT cells expressing
cell surfaceTNF is shown, as determined by FAGS analyses of cells labeled with IgGl antiTNF mAb
and FITC-goat anti-mouse IgGl . Nonspecific fluorescence wasdetermined by labeling cells with IgGl
control mAb and FITC-goat anti-mouse IgGI (TPA, 1 ng/ml ; ionomycin, 0.5 ,UM; CsA, 100 ng/ml ;
and MP, 100 WM). (Fig 4, right) Transcriptional activation ofTNF gene and the inhibitory effect of
CsA andMP on TNFmRNA accumulation . Total cellular RNA was isolated from T cells and assayed
for TNFmRNA by Northern blot analysis. Test conditions : lane 1, T cells incubated alone; lane 2,
T cells + TPA and ionomycin; Lane 3, T cells + CsA + TPA and ionomycin ; Lane 4, T cells +
MP + TPAandionomycin. 18sand28s indicate positions ofribosomalRNA(TPA, 1 ng/ml ; ionomycin,
0.5 uM ; CsA, 100 ng/ml ; MP, 100 pM) .
tion by CsA (lane 3) and by MP (lane 4). These results suggest that CsA or MP
inhibit T cell surface expression of TNF at a pretranslational site .
Summary
Expression of the pluripotent molecule TNF in a focused and antigen-restricted
fashion might provide an advantage to the host organism . Given the central role
ofT cells in antigen-specific immunity, we examined whether activatedT cells ex-
press TNF on their cell surface . FRCS analysis of highly purified normal human
T cells labeledwith an antiTNFmAb revealed that T cells express cell surfaceTNF
when signaled with the synergistic combination ofacalciumionophore, ionomycin,
and a protein kinase C activator, 12-o-tetradecanoyl phorbol acetate . Cell surface946
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radioiodination studies of stimulated T cells demonstrated the presence of 26-kD
transmembrane protein, a size predicted by TNF cDNA and different from that
of the 17-kD secreted TNF molecule. The induced cell surface expression of TNF
could be blocked with cyclosporine and/or methylprednisolone, and Northern anal-
ysis for TNFspecific transcripts revealed that this inhibitory effect occurs pretrans-
lationally. Our demonstration for the first time that stimulated normal human T
cellsdisplay cell surface TNF provides a mechanistic basis for the realization ofeffects
of TNF in an antigen-specific fashion.
Receivedfor publication 1 November 1989 and in revisedform 11 December 1989.
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